Article Information
History
- November 2, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- J Zuo1,*,
- A Dowell1,*,
- H Pearce1,*,
- K Verma1,*,
- HM Long1,
- J Begum1,
- F Aiano2,
- Z Amin-Chowdhury2,
- B Hallis3,
- L Stapley3,
- R Borrow4,
- E Linley4,
- S Ahmad5,
- B Parker6,
- A Horsley7,
- G Amirthalingam2,
- K Brown2,
- ME Ramsay2,
- S Ladhani2,8,* and
- P Moss1,*,#
- 1Institute of Immunology and Immunotherapy, University of Birmingham, UK. B15 2TA
- 2Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ
- 3Immunoassay Lab, National Infection Service, Porton Down SP4 0JG
- 4Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL
- 5The NIHR Manchester Clinical Research Facility at Wythenshawe Hospital, Charles Blackley Ward, North West Lung Research Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, South moor Road, Manchester, M23 9LT
- 6NIHR Manchester Clinical Research Facility, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL & Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, M13 9WL
- 7University of Manchester and NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester M23 9LT
- 8Paediatric Infectious Diseases Research Group (PIDRG), St. Georges University of London, (SGUL), London, UK
- ↵#Corresponding author; email: p.moss{at}bham.ac.uk
↵* Equal contribution
Posted November 02, 2020.
Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection
